The new PubMed site will become the default in mid-May. Click here to try it now! Frequently asked questions
Format

Send to

Choose Destination
Oncol Lett. 2013 Aug;6(2):556-558. Epub 2013 May 30.

Small compound 6-O-angeloylplenolin induces caspase-dependent apoptosis in human multiple myeloma cells.

Author information

1
The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and BioMedicine and Division of Life Sciences, Shenzhen Graduate School, Tsinghua University, Shenzhen, Guangdong 518055, P.R. China.

Abstract

6-O-angeloylplenolin (6-OAP) is a sesquiterpene lactone agent that has been previously demonstrated to inhibit the growth of multiple myeloma (MM) cells through mitotic arrest with accumulated cyclin B1. In the present study, the levels of apoptosis were analyzed in dexamethasone-sensitive (MM.1S), dexamethasone-resistant (U266) and chemotherapy-sensitive (RPMI 8226) myeloma cell lines. Enhanced apoptosis was identified following a 48-h incubation with 6-OAP (0-10 μM) that induced a dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, anti-poly (ADP-ribose) polymerase (PARP). In addition, time-dependent cleavage of PARP was also detected in U266 and MM.1S cells. The mechanism of 6-OAP cytotoxicity in all cell lines was associated with the induction of apoptosis with the presence of cleaved caspase-3 and PARP. In conclusion, 6-OAP-induced apoptosis is caspase-dependent. These observations are likely to provide a framework for future studies of 6-OAP therapy in MM.

KEYWORDS:

6-O-angeloylplenolin; apoptosis; caspase; multiple myeloma

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center